Transforming Cancer Care:
From Treating a Diagnosis to Treating the Patient
BostonGene provides comprehensive molecular and immune profiling to assist in treatment selection
Why BostonGene
Partners
-
Strategic alliance with MD Anderson to advance personalized cancer diagnostics and treatments. -
BostonGene announces new master agreement with New York’s Memorial Sloan Kettering Cancer Center -
Mayo Clinic and BostonGene collaborate to uncover key tumor characteristics that can be exploited to develop personalized therapies for lymphoma patients
BostonGene Approach
Our AI-based molecular and immune profiling identifies the most effective treatment options for every cancer patient
Diagnose
Comprehensive testing for each cancer patient
Predict and Monitor
Cancer therapy response
Innovate
The landscape of precision medicine
Simplify
User-friendly treatment guidelines for care teams
Discover
New tools for oncologists
Evolve
Cancer profiling databases
News
BostonGene Announces Integration with NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
BostonGene Announces the Launch of its CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling and Spatial Proteomics Solutions
MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer
- BostonGene Announces Integration with NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
- BostonGene Announces the Launch of its CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling and Spatial Proteomics Solutions
- MD Anderson EGFR Classification licensed by BostonGene and Tempus to provide new insight on atypical mutations in lung cancer
Questions
Contact us